MX2015014423A - Administración efectiva de genes grandes por vectores aav duales. - Google Patents
Administración efectiva de genes grandes por vectores aav duales.Info
- Publication number
- MX2015014423A MX2015014423A MX2015014423A MX2015014423A MX2015014423A MX 2015014423 A MX2015014423 A MX 2015014423A MX 2015014423 A MX2015014423 A MX 2015014423A MX 2015014423 A MX2015014423 A MX 2015014423A MX 2015014423 A MX2015014423 A MX 2015014423A
- Authority
- MX
- Mexico
- Prior art keywords
- aav vectors
- effective delivery
- dual aav
- large genes
- genes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
- C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a construcciones, vectores, células hospederas y composiciones farmacéuticas relativas que permiten una terapia genética eficaz, en particular de genes más grandes de 5kb.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361813342P | 2013-04-18 | 2013-04-18 | |
PCT/EP2014/058000 WO2014170480A1 (en) | 2013-04-18 | 2014-04-18 | Effective delivery of large genes by dual aav vectors |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015014423A true MX2015014423A (es) | 2016-07-28 |
MX365711B MX365711B (es) | 2019-06-11 |
Family
ID=50678160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015014423A MX365711B (es) | 2013-04-18 | 2014-04-18 | Administración efectiva de genes grandes por vectores aav duales. |
Country Status (11)
Country | Link |
---|---|
US (1) | US10494645B2 (es) |
EP (1) | EP2986635B1 (es) |
JP (1) | JP6453307B2 (es) |
CN (1) | CN105408352B (es) |
AU (1) | AU2014255665B2 (es) |
CA (1) | CA2909733C (es) |
DK (1) | DK2986635T3 (es) |
EA (1) | EA034575B1 (es) |
ES (1) | ES2704677T3 (es) |
MX (1) | MX365711B (es) |
WO (1) | WO2014170480A1 (es) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
CA3066596A1 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Cns targeting aav vectors and methods of use thereof |
CA2833905C (en) | 2010-04-23 | 2019-09-10 | University Of Massachusetts | Multicistronic expression constructs |
WO2013075008A1 (en) | 2011-11-16 | 2013-05-23 | University Of Florida Research Foundation Inc. | Aav dual vector systems for gene therapy |
WO2015127128A2 (en) | 2014-02-19 | 2015-08-27 | University Of Massachusetts | Recombinant aavs having useful transcytosis properties |
WO2015143078A1 (en) | 2014-03-18 | 2015-09-24 | University Of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
US10689653B2 (en) | 2014-06-03 | 2020-06-23 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
RU2738421C2 (ru) | 2014-10-21 | 2020-12-14 | Юниверсити Оф Массачусетс | Варианты рекомбинантных aav и их применения |
RU2020109343A (ru) | 2014-11-05 | 2020-03-17 | Вояджер Терапьютикс, Инк. | Полинуклеотиды aadc для лечения болезни паркинсона |
DK3218386T3 (da) | 2014-11-14 | 2021-06-07 | Voyager Therapeutics Inc | Modulatorisk polynukleotid |
MX2017006216A (es) | 2014-11-14 | 2018-08-29 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). |
US10584321B2 (en) | 2015-02-13 | 2020-03-10 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
BR112017018728A2 (pt) * | 2015-03-03 | 2018-04-17 | Fond Telethon | sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada |
CA3021949C (en) | 2015-04-24 | 2023-10-17 | University Of Massachusetts | Modified aav constructs and uses thereof |
JP2018522834A (ja) | 2015-06-04 | 2018-08-16 | インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) | 遺伝子治療による眼疾患治療のための改良された方法 |
WO2017070525A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance in neurodegenerative disease |
WO2017070516A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
CA3005474A1 (en) | 2015-11-19 | 2017-05-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for correction of heritable ocular disease |
RU2762747C2 (ru) | 2015-12-14 | 2021-12-22 | Зе Трастис Оф Зе Юниверсити Оф Пенсильвания | Генная терапия офтальмологических нарушений |
US11072803B2 (en) | 2015-12-22 | 2021-07-27 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Hybrid dual recombinant AAV vector systems for gene therapy |
US11826433B2 (en) | 2016-02-02 | 2023-11-28 | University Of Massachusetts | Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system |
EP4094780A3 (en) | 2016-02-12 | 2023-02-08 | University of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
EP3440210A4 (en) | 2016-04-05 | 2019-11-27 | University of Massachusetts | COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF EXPRESSION OF GRAINHEAD PROTEIN |
WO2017181105A1 (en) | 2016-04-15 | 2017-10-19 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
CN109831916B (zh) | 2016-05-18 | 2023-07-21 | 沃雅戈治疗公司 | 治疗亨廷顿氏舞蹈病的组合物和方法 |
IL302748A (en) | 2016-05-18 | 2023-07-01 | Voyager Therapeutics Inc | modulatory polynucleotides |
WO2017218852A1 (en) | 2016-06-15 | 2017-12-21 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
BR112018075855A2 (pt) * | 2016-06-15 | 2019-04-02 | Oxford University Innovation Limited | sistema de vetor viral adeno-associado com dupla sobreposição para a expressão abc4a |
CN110225975A (zh) | 2016-08-23 | 2019-09-10 | 阿库斯股份有限公司 | 用于治疗人受试者中非年龄相关的听力损害的组合物和方法 |
EP3831281A1 (en) | 2016-08-30 | 2021-06-09 | The Regents of The University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
KR20190075964A (ko) | 2016-10-13 | 2019-07-01 | 유니버시티 오브 매사추세츠 | Aav 캡시드 설계 |
US11541131B2 (en) | 2017-03-10 | 2023-01-03 | Genethon | Treatment of glycogen storage disease III |
JP7307480B2 (ja) * | 2017-04-05 | 2023-07-12 | ユニバーシティ オブ マサチューセッツ | ミニ遺伝子療法 |
WO2018195555A1 (en) * | 2017-04-21 | 2018-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors |
CN110913866A (zh) | 2017-05-05 | 2020-03-24 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
CA3061955A1 (en) * | 2017-05-05 | 2018-11-08 | University Of Florida Research Foundation, Incorporated | Compositions and methods for expressing otoferlin |
WO2018208972A1 (en) | 2017-05-09 | 2018-11-15 | University Of Massachusetts | Methods of treating amyotrophic lateral sclerosis (als) |
JP2020527335A (ja) | 2017-06-14 | 2020-09-10 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 眼疾患のための遺伝子療法 |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
WO2019018342A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | NETWORK EQUIPMENT TRACK GUIDE SYSTEM |
EP3662060A2 (en) | 2017-08-03 | 2020-06-10 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
JP7397488B2 (ja) | 2017-09-22 | 2023-12-13 | ユニバーシティ オブ マサチューセッツ | Sod1二重発現ベクターおよびその使用 |
EP3696271A4 (en) * | 2017-10-11 | 2021-05-19 | Celltrion Inc. | EXPRESSION CASSETTE FOR THE PRODUCTION OF A HIGH EXPRESSION AND HIGH FUNCTIONALITY TARGET PROTEIN AND ITS USE |
US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
JP7502991B2 (ja) | 2017-10-16 | 2024-06-19 | ボイジャー セラピューティクス インコーポレイテッド | 筋萎縮性側索硬化症(als)の治療 |
CA3091676A1 (en) * | 2018-02-22 | 2019-08-29 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
JP2021520231A (ja) | 2018-04-05 | 2021-08-19 | オックスフォード ユニバーシティ イノベーション リミテッドOxford University Innovation Limited | シュタルガルト病の処置のための組成物及び方法 |
AU2019255708A1 (en) * | 2018-04-17 | 2020-11-26 | Ascidian Therapeutics, Inc. | Trans-splicing molecules |
US11660353B2 (en) * | 2018-04-27 | 2023-05-30 | Decibel Therapeutics, Inc. | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems |
EP3821019A4 (en) * | 2018-07-13 | 2022-10-05 | Akouos, Inc. | METHODS OF TREATMENT OF NONSYNDROMIC INNER EAR DEAF |
CN109136266B (zh) * | 2018-08-10 | 2022-02-18 | 深圳泓熙生物科技发展有限公司 | 用于治疗或预防结晶样视网膜色素变性的基因载体及其用途 |
US20210371878A1 (en) | 2018-10-15 | 2021-12-02 | Fondazione Telethon | Intein proteins and uses thereof |
WO2020093018A1 (en) * | 2018-11-01 | 2020-05-07 | University Of Florida Research Foundation, Incorporated | A codon optimized otoferlin aav dual vector gene therapy |
CA3119059A1 (en) * | 2018-11-07 | 2020-05-14 | Akouos, Inc. | Compositions and methods of inducing differentiation of a hair cell |
EP3880826A4 (en) * | 2018-11-07 | 2022-08-24 | Akouos, Inc. | USE OF ADENO-ASSOCIATED VIRAL VECTORS TO CORRECT GENE DEFECTS/EXPRESS PROTEINS IN CILIATE AND SUPPORTING CELLS IN THE INNER EAR |
US20220160898A1 (en) * | 2018-12-10 | 2022-05-26 | Vigeneron Gmbh | An optimized acceptor splice site module for biological and biotechnological applications |
WO2020214990A1 (en) * | 2019-04-17 | 2020-10-22 | Ascidian Therapeutics, Inc. | Abca4 cell line and methods of use |
CN114402075A (zh) * | 2019-04-19 | 2022-04-26 | 马萨诸塞大学 | 乌谢尔综合征(ush2a)的基因疗法 |
EP3956453A4 (en) * | 2019-04-19 | 2023-02-22 | University of Massachusetts | GENE THERAPIES FOR USHER SYNDROME (USH1B) |
US20220233720A1 (en) * | 2019-05-20 | 2022-07-28 | University Of Massachusetts | Minigene therapy |
JP2022538598A (ja) * | 2019-06-25 | 2022-09-05 | ミガル ガリラヤ リサーチ インスティテュート リミテッド | プレmRNAのトランススプライシングに基づく合成転写用論理「AND」ゲートを作製するためのシステムおよびその使用 |
US20220267802A1 (en) * | 2019-07-15 | 2022-08-25 | President And Fellows Of Harvard College | Methods and compositions for gene delivery |
CN113122657B (zh) * | 2019-12-31 | 2022-07-29 | 上海吉凯基因医学科技股份有限公司 | 一种多重aav病毒滴度的检测方法 |
WO2021168362A1 (en) | 2020-02-21 | 2021-08-26 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
CN115666658A (zh) * | 2020-04-01 | 2023-01-31 | 佛罗里达州大学研究基金会 | 具有提高的治疗ush1b的安全性的双aav-myo7a载体 |
JP2023523622A (ja) * | 2020-04-29 | 2023-06-06 | サリオジェン セラピューティクス インコーポレイテッド | 遺伝性黄斑変性症の治療のための組成物及び方法 |
CN111926085B (zh) * | 2020-08-21 | 2022-05-31 | 云南农业大学 | 一种影响鸡肌肉亮度的分子标记及其应用 |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
WO2022174146A1 (en) * | 2021-02-12 | 2022-08-18 | Greffex, Inc. | Gene therapy for retinal diseases |
US11603541B2 (en) * | 2021-05-06 | 2023-03-14 | Kinase Pharma Inc. | Compositions and method of making a complex able to increase production of a cetuximab-like protein (CLP) in a target cell |
CA3218631A1 (en) * | 2021-05-12 | 2022-11-17 | Alberto Auricchio | Vector system |
CN115074369B (zh) * | 2022-06-24 | 2023-10-20 | 成都金唯科生物科技有限公司 | 表达全长abca4基因的腺相关病毒载体及应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0356130A3 (en) * | 1988-08-22 | 1991-09-11 | Genencor International, Inc. | A mobile fl phage single-strand dna origin of replication |
US6255071B1 (en) * | 1996-09-20 | 2001-07-03 | Cold Spring Harbor Laboratory | Mammalian viral vectors and their uses |
FR2763959A1 (fr) * | 1997-06-02 | 1998-12-04 | Transgene Sa | Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage |
GB9720465D0 (en) * | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
US6846970B1 (en) * | 1999-07-19 | 2005-01-25 | Plant Bioscience Limited | Transformation method and transgenic plants produced thereby |
US7250406B2 (en) * | 2002-04-19 | 2007-07-31 | Georgia Tech Research Corporation | Compositions and methods for the acceleration of protein secretion dynamics |
US8470965B2 (en) * | 2006-03-01 | 2013-06-25 | University Of Utah Research Foundation | Methods and compositions related to cyclic peptide synthesis |
US20100120665A1 (en) * | 2007-03-01 | 2010-05-13 | Advanced Vision Therapies, Inc. | Treatment of diseases characterized by inflammation |
US20090214478A1 (en) * | 2008-02-21 | 2009-08-27 | Alberto Auricchio | Method of treating ocular diseases by gene therapy |
US8236557B2 (en) * | 2008-05-28 | 2012-08-07 | University Of Missouri-Columbia | Hybrid-AAV vectors to deliver large gene expression cassette |
WO2013075008A1 (en) * | 2011-11-16 | 2013-05-23 | University Of Florida Research Foundation Inc. | Aav dual vector systems for gene therapy |
-
2014
- 2014-04-18 WO PCT/EP2014/058000 patent/WO2014170480A1/en active Application Filing
- 2014-04-18 JP JP2016508186A patent/JP6453307B2/ja active Active
- 2014-04-18 EP EP14721802.8A patent/EP2986635B1/en active Active
- 2014-04-18 CA CA2909733A patent/CA2909733C/en active Active
- 2014-04-18 US US14/785,229 patent/US10494645B2/en active Active
- 2014-04-18 ES ES14721802T patent/ES2704677T3/es active Active
- 2014-04-18 CN CN201480035105.9A patent/CN105408352B/zh active Active
- 2014-04-18 MX MX2015014423A patent/MX365711B/es active IP Right Grant
- 2014-04-18 EA EA201591992A patent/EA034575B1/ru not_active IP Right Cessation
- 2014-04-18 AU AU2014255665A patent/AU2014255665B2/en active Active
- 2014-04-18 DK DK14721802.8T patent/DK2986635T3/en active
Also Published As
Publication number | Publication date |
---|---|
JP2016516424A (ja) | 2016-06-09 |
CN105408352A (zh) | 2016-03-16 |
AU2014255665B2 (en) | 2018-08-02 |
CA2909733C (en) | 2023-10-17 |
EP2986635A1 (en) | 2016-02-24 |
DK2986635T3 (en) | 2019-01-28 |
ES2704677T3 (es) | 2019-03-19 |
WO2014170480A1 (en) | 2014-10-23 |
US10494645B2 (en) | 2019-12-03 |
CN105408352B (zh) | 2020-01-14 |
JP6453307B2 (ja) | 2019-01-16 |
BR112015026422A2 (pt) | 2017-11-14 |
US20160076054A1 (en) | 2016-03-17 |
AU2014255665A1 (en) | 2015-11-12 |
EP2986635B1 (en) | 2018-10-03 |
CA2909733A1 (en) | 2014-10-23 |
MX365711B (es) | 2019-06-11 |
EA034575B1 (ru) | 2020-02-21 |
EA201591992A1 (ru) | 2016-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX365711B (es) | Administración efectiva de genes grandes por vectores aav duales. | |
MX2023004479A (es) | Sistema de vector multiple y sus usos. | |
MX2017014125A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
IN2014DN08812A (es) | ||
EP4273238A3 (en) | Compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity | |
MX2017007731A (es) | Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas. | |
MX2019005158A (es) | Variantes de glucoamilasa y polinucleotidos que las codifican. | |
EP3741849A3 (en) | Protease variants and polynucleotides encoding same | |
MX355356B (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
MX337984B (es) | Variantes de alfa amilasa y polinucleotidos que codifican la misma. | |
MX2021009118A (es) | Composiciones y metodos para inhibir la expresion del gen alas1. | |
WO2012112578A3 (en) | Improved aav8 vector with enhanced functional activity and methods of use thereof | |
MX354704B (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
MX351762B (es) | Variantes de glucoamilasas y polinucleotidos que las codifican. | |
MX2019000140A (es) | Variantes de xilanasa y polinucleotidos que las codifican. | |
MX2015014851A (es) | Vacuna de adn que dirige wt-1 novedosa para inmunoterapia del cancer. | |
MX2021013104A (es) | Variantes de lipasa y polinucleotidos que las codifican. | |
MX2021004391A (es) | Proteinas inteinas y usos de las mismas. | |
MX2015000312A (es) | Polipeptidos que tienen actividad lipasa y polinucleotidos que los codifican. | |
EP3321360A3 (en) | Alpha-amylase variants and polynucleotides encoding same | |
WO2014195356A3 (en) | Alpha-amylase variants and polynucleotides encoding same | |
EP2987504A4 (en) | NON-VIRAL GENE DELIVERY SYSTEM FOR TARGETING ADIPOSE CELLS | |
MX2022001017A (es) | Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1). | |
EP3256590A4 (en) | Targeting oligonucleotides and uses thereof to modulate gene expression | |
IN2014CN03187A (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |